propiolactone and 2019 Novel Coronavirus Disease

propiolactone has been researched along with 2019 Novel Coronavirus Disease in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	8 (100.00)	2.80

Authors

Authors	Studies
Gupta, D; Harshan, KH; Parthasarathy, H; Reddy, S; Sah, V; Tandel, D; Vedagiri, D	1
Bagrov, DV; Egorov, AM; Glukhov, GS; Ishmukhametov, AA; Ivin, YY; Karlova, MG; Kirpichnikov, MP; Kovpak, AA; Kozlovskaya, LI; Litvinov, DS; Moiseenko, AV; Oksanich, AS; Osolodkin, DI; Piniaeva, AN; Shaitan, KV; Shishova, AA; Sokolova, OS; Volok, VP; Zaitsev, PА	1
Chang, Z; Ji, W; Li, J; Li, W; Liang, H; Liu, Y; Wang, H; Wang, Y; Wei, Y; Wu, H; Xie, S; Yang, X; Yu, S	1
Kordyukova, LV; Lioznov, DA; Moiseenko, AV; Serebryakova, MV; Sergeeva, MV; Shanko, AV; Shuklina, MA	1
Addo, MM; Fathi, A; Jendrny, P; Meller, S; Osterhaus, A; Pilchová, V; Pink, I; Prajeeth, CK; Schulz, C; Twele, F; Volk, HA; von Köckritz-Blickwede, M	1
Basler, CF; Jureka, AS; Silvas, JA	1
Chen, W; Du, J; Duan, K; Gao, X; Guo, J; Guo, W; Huang, L; Huang, S; Li, X; Lu, J; Meng, Z; Pan, A; Peng, C; Shen, S; Shi, Z; Wan, X; Wang, Q; Wang, W; Wang, X; Wang, Y; Wang, Z; Wu, C; Xia, S; Xie, Z; Yang, X; Yang, Y; You, W; Yuan, Z; Zhang, H; Zhang, L; Zhang, W; Zhang, Y; Zhao, D; Zhou, W	1
Arankalle, V; Kulkarni, R; Lalwani, S; Mishra, AC; Palkar, S; Patil, HP	1

Reviews

1 review(s) available for propiolactone and 2019 Novel Coronavirus Disease

Article	Year
β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training. Journal of virological methods, 2023, Volume: 317 Topics: Animals; COVID-19; Dogs; Odorants; Propiolactone; Saliva; SARS-CoV-2; Virus Inactivation; Viruses	2023

Trials

1 trial(s) available for propiolactone and 2019 Novel Coronavirus Disease

Article	Year
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 2020, 09-08, Volume: 324, Issue:10 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aluminum Hydroxide; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Dose-Response Relationship, Immunologic; Double-Blind Method; Female; Humans; Immunogenicity, Vaccine; Injections, Intramuscular; Male; Pandemics; Pneumonia, Viral; Propiolactone; SARS-CoV-2; Vaccines, Inactivated; Viral Vaccines; Young Adult	2020

Article

Year

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.

JAMA, 2020, 09-08, Volume: 324, Issue:10

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aluminum Hydroxide; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Dose-Response Relationship, Immunologic; Double-Blind Method; Female; Humans; Immunogenicity, Vaccine; Injections, Intramuscular; Male; Pandemics; Pneumonia, Viral; Propiolactone; SARS-CoV-2; Vaccines, Inactivated; Viral Vaccines; Young Adult

2020

Other Studies

6 other study(ies) available for propiolactone and 2019 Novel Coronavirus Disease

Article	Year
Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential. Virus research, 2021, Volume: 305 Topics: Animals; Antigens, Viral; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Vaccines; Flocculation; Humans; Immune Sera; Propiolactone; RNA, Viral; SARS-CoV-2; Vaccines, Inactivated; Vero Cells; Virion; Virus Inactivation	2021
Structural characterization of β-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. Microscopy research and technique, 2022, Volume: 85, Issue:2 Topics: Animals; Chlorocebus aethiops; COVID-19; Humans; Pandemics; Propiolactone; SARS-CoV-2; Vaccines, Inactivated; Vero Cells	2022
Comparison of Physical and Biochemical Characterizations of SARS-CoV-2 Inactivated by Different Treatments. Viruses, 2022, 08-31, Volume: 14, Issue:9 Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Formaldehyde; Humans; Propiolactone; SARS-CoV-2; Vaccines, Inactivated	2022
Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine. Viruses, 2023, 02-09, Volume: 15, Issue:2 Topics: Animals; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Formaldehyde; Humans; Pandemics; Propiolactone; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Inactivated	2023
Propagation, Inactivation, and Safety Testing of SARS-CoV-2. Viruses, 2020, 06-06, Volume: 12, Issue:6 Topics: Animals; Betacoronavirus; Cellulose; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Culture Media; Formaldehyde; Guanidines; HEK293 Cells; Humans; Pandemics; Phenols; Pneumonia, Viral; Propiolactone; SARS-CoV-2; Sepharose; Vero Cells; Viral Plaque Assay; Virus Inactivation	2020
Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA. Journal of virological methods, 2021, Volume: 287 Topics: Antibodies, Viral; COVID-19; COVID-19 Serological Testing; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Propiolactone; SARS-CoV-2; Sensitivity and Specificity; Seroepidemiologic Studies; Virus Inactivation	2021